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CI1.05-1.89; p= 0.024). MI were slightly less likely to schedule DFE vs. UC (38% vs. 
42%, RR0.90; CI0.66-1.22; p= NSS) and attend DFE (32% vs. 36%; RR0.90; CI 0.63-1.28; 
p= NSS). The total cost of TI was $603.98 or $5.03/participant and the cost/follow-up 
DFE was $26.05. Sensitivity analyses revealed that the cost/follow-up can be greatly 
reduced but remains additional vs. UC ($2.76 if $0.25/call, $11.13 if $1/call; $22.29 
if $2/call). ConClusions: Personal phone assistance in scheduling DFE follow-
up assistance is more effective but also more costly. Follow-up research has been 
initiated to determine whether automated phone reminders can achieve similar 
effectiveness at a lower cost.
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objeCtives: Compare health care resource utilization and costs of Cushing disease 
(CD) cases to CD-free controls. Methods: A retrospective matched-cohort study 
design was used to analyze the administrative claims of commercial health plan 
enrollees with evidence of CD from 2007-2011. CD cases were matched 1:3 to CD-free 
controls by age, sex, region, and index year. CD cases were identified using a Cushing 
syndrome diagnosis code (ICD-9: 255.0) and codes for a CD-related diagnosis or 
procedure (e.g., pituitary neoplasm or hypophysectomy). CD cases were observed for 
≥ 6 months after their first CD-related claim. Controls were observed starting in the 
same index year. Per-patient-per-month (PPPM) counts and costs of all-cause health 
care resource utilization were compared descriptively. Costs were CPI-adjusted to 
2011 dollars and included health plan- and patient-paid amounts. Results: Among 
the 885 selected CD cases and 2,655 matched controls, the mean (SD) age was 42 
(14) years and 75% were female. Median follow-up was 2.4 years for cases and 1.5 
years for controls. Compared to controls, cases had a higher proportion of inpa-
tient admissions (50% vs. 11%; p< 0.001), emergency department visits (61% vs. 20%; 
p< 0.001), and outpatient visits (95% vs. 63%; p< 0.001). Average monthly counts of 
utilization for cases were 2-4 times higher than controls: ambulatory visits (2.5 vs. 
0.9; p< 0.001), ED visits (0.1 vs. 0.04; p< 0.001), and inpatient admissions (0.03 vs. 0.01; 
p< 0.001). Average PPPM total all-cause costs were also higher for cases than controls 
($3,224 vs. $486; p< 0.001), and were largely driven by medical costs ($2,790 vs. $382; 
p< 0.001). Average PPPM pharmacy costs were 4 times higher for cases than controls 
($434 vs. $104; p< 0.001). ConClusions: In this study, high health care resource 
utilization and costs were identified for CD cases compared to CD-free controls. In 
addition to CD treatment costs, differences included the costs of diagnosing and 
treating the multiple comorbidities often observed in CD patients.
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objeCtives: In Ukraine COPD is significant medical and socio-economic prob-
lem. The aim of this study was to assess and compare the 2013 annual exacerba-
tion-related direct costs in COPD stages subpopulations. Methods: Costs were 
assessed with State Budget perspective. Inpatient costs included service costs and 
costs for diagnostic procedures. Outpatient costs included physician visits and 
spirometry costs. Epidemiological and cost data were obtained from the appro-
priate 2012-2020 model. Data about the proportions of I-IV COPD were obtained 
from Ukrainian study: I, II, III and IV was 20%, 44%, 29% and 7%, respectively. Data 
about annual exacerbations and hospitalizations rates were obtained from GOLD 
2013: I: no data; II:0.7-0.9 and 0.11-0.2; III:1.1-1.3 and 0.25-0.3; VI:1.2-2.0 and 0.4-0.54, 
respectively. We made an assumption that the annual number of exacerbation led 
to outpatient visits was the difference between total exacerbations rate and hos-
pitalization rate (2 outpatient visits per exacerbation). Costs were considered in 
minimal and maximal exacerbation rates scenarios and were calculated per sub-
population and per patient. 11% inflation rate, 17.6% social-tax and 17% VAT were 
applied. Exchange rate 1USD= 7.99UAH on 30.12.2013. Results: In 2013 number 
of COPD patients in Ukraine was 581,598. Number of patients with I, II, III and IV 
stages could amount 116,320; 255,903; 168,663 and 40,712, respectively. Minimal-
maximal annual inpatient costs in II, III and IV COPD subpopulations could amount 
$6,310,192.66-$11,473,077.56 ($25.00-$45.00 per patient), $9,452,232.30-$11,342,678.76 
($56.04-$67.25 per patient) and $3,650,538.95-$4,928,227.58 ($90.00-$121.00 per 
patient), respectively. Minimal-maximal annual outpatient costs in II, III and IV 
subpopulations could amount $859,721.71-$1,355,712.42 ($3.36-$5.30 per patient), 
$1,253,374.56-$1,645,054.12 ($7.43-$9.75 per patient) and $889,441.63-$2,156,222.13 
($21.85-$52.96 per patient), respectively. ConClusions: Total direct costs were 
largest in COPD III patients, but per-patient direct costs were largest in COPD IV. So, 
in case of COPD-related costs assessment the stratification of patients by airflow 
limitation and exacerbations rates should be taken in account.
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objeCtives: Estimate the cost of treating hypoglycemic events in patients with 
type 2 diabetes mellitus (DM2), in the Mexican public health care system using 
data from two databases and to compare these costs according to hypoglycemic 
event severity. Methods: A Cost Analysis was developed to estimate the economic 
impact of treating hypoglycemic events. Definition of hypoglycemia was according 
with the published by Jonsson and colleagues1: Mild, Moderate and Severe. The use 
of resources was validated with an expert panel of specialists from the public health 
system. Only direct costs were used in this analysis. Estimates were obtained from 
I2= 18%]. Having an end-of-life, hospice, or palliative care facility in the nursing home 
increased the likelihood of dying in a nursing home vs. hospital (OR 7.79 [2.22–27.31], 
4 studies, I2= 98%). ConClusions: Availability of services influences the site of 
death. For patients preferring death at home, the presence of a multidisciplinary 
home care team is one of the factors that can support home death.
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objeCtives: This study was conducted to evaluate the appropriate use of medi-
cines among the hospitalized patients with renal impairment. Methods: Study 
Design:The study was a retrospective study in which medication charts (prescription 
and laboratory reports) of patients were used to evaluate appropriate use of medi-
cines. Setting: Data was collected from nephrology departments of selected hospitals 
of Gujarat, Bahawalpur and Lahore. Main outcome measure: Percentage of prescrip-
tions containing contraindicated drugs, percentage of prescriptions containing 
drugs prescribed without adjusting their doses, percentage of prescriptions contain-
ing drug-drug interactions and percentage of drugs prescribed without specifying 
any dose. Results: About 500 prescriptions of patients (male and female) with 
moderate and severe renal impairment were collected and evaluated. According 
to this study, contraindicated drugs were observed in 30.8% prescriptions, drugs 
prescribed without dose adjustment were found in 51% prescriptions, drug-drug 
interactions were observed in 63.6% prescriptions and drugs prescribed without 
any specific dosage regimen in 4.8% prescriptions. At least one drug interaction was 
found in each prescription (median = 1, inter quartile range = 1-6). ConClusions: 
This study showed the negligence of health care providers especially physicians 
and nephrologists. The study provided evidence that either physicians do not take 
notice of patient’s renal function while prescribing or are incompetent enough to 
take such measures. Interventions are required to improve the prescribing quality 
and prescribers’ behaviors that will ultimately improve the quality of care.
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objeCtives: The Post-Licensure Rapid Immunization Safety Monitoring (PRISM) pro-
gram was created in response to the need of the U.S. Food and Drug Administration 
(FDA) to monitor the safety of H1N1influenza vaccine. Later PRISM was incorporated 
into the FDA’s Mini-Sentinel Initiative to evaluate the safety of other vaccines. We 
describe the distributed data structure used in this system. Methods: PRISM uses 
a distributed data method whereby claims data processed through 3 health insur-
ance companies, “Data Partners,” are organized into a standardized common data 
model (CDM). Data in this standard format are refreshed on a quarterly basis and 
stored by the Data Partners. Mini-Sentinel programs are run on these data to extract 
aggregate data for analysis. The data in the CDM are augmented by linking to eight 
state and city Immunization Information Systems (IIS) to obtain additional vaccine 
exposure data. Results: The CDM includes 110 million lives, 2.6 billion dispensing, 
and 3.1 billion health care encounters from 2004-2012 from the three Data Partners, 
representing three major health insurance companies. The vaccine data from the 
state IIS improve the completeness of vaccine information for individuals. In 2012, 
unrestricted (including states even if they did not contribute data) analysis showed 
that IIS contributed an additional 5-9% of vaccine administration data. In the chart 
validation assessing the risk of intussusception following rotavirus vaccination, 
it was identified that 46% (124/267) of cases identified by the electronic algorithm 
were true intussusception cases. Reports on one vaccine safety assessment has 
been completed. ConClusions: Vaccines are an essential component to maintain 
public health. The benefits of the PRISM system include the large pooled population, 
enhanced ability to capture data from alternative sources, and ability to evaluate the 
potential risks of rare adverse events; the distributed data model ensures patient 
confidentiality. Validation by chart review adds precision to the evaluations.
HEaLtH SErvicES – cost Studies
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objeCtives: To compare effectiveness and costs of personal reminder approaches 
(mailed vs. phone) to improve dilated fundus examination (DFE) follow-up adher-
ence in patients with diabetes. Methods: In a prospective trial, 356 diabetics due 
for DFE were randomly assigned to usual care (UC; reference case), mailed interven-
tion (MI), or telephone intervention (TI). UC (n= 119) received a standard form letter. 
MI (n= 117) received a personalized letter encouraging scheduling of eye examina-
tion with an educational brochure about diabetic eye disease. TI (n= 120) received 
personal calls (up to 3 attempts) to schedule a follow-up with standard form letter. 
The primary outcome was DFE within 90 days of suggested return. Costs ($US 2013) 
included time costs (staff time in preparing letters, conducting calls, and documen-
tation converted to dollars using wages + benefit costs), phone charges, supplies, 
and postage. Since TI dominated MI, univariate sensitivity analysis examined the 
impact of reducing phone costs. Results: Participants were mostly female (66%) 
and African-American (70%) with a mean age of 61 years. TI were more likely to 
schedule DFE (65% vs. 42%; RR1.54; CI1.20-1.96; p< 0.001) vs. UC. DFE within 90 days 
of suggested return in TI was also significantly higher than UC (51% vs. 36%, RR1.41; 
